The North America Gastrointestinal Therapeutics Market should witness market growth of 2.6% CAGR during the forecast period (2022-2028).
In many ways, the intestinal milieu represents a microcosm of the whole body. It possesses its intrinsic endocrine and nervous system, its barrier both to internal and external environments of the body, and its own intrinsic mucosal immune system, namely the so-called gut-associated lymphoid tissue (GALT).
Each of these enteric systems can account for pathophysiology and contribute to digestive disorders' clinical picture. Thus, therapeutic intervention for the disease of the GI tract is particularly demanding and should be strategically targeted, with the potential for drug side effects representing considerable accountability.
Gastrointestinal (GI) disease may affect one or more gastrointestinal tract regions, including the esophagus, small & large intestine, stomach, or accessory organs such as the pancreas, gallbladder, and liver. This disease class includes both structural and functional disorders. In addition, GI disorders may arise from diverse etiologies, including pathogens exposure, certain medications, stress, diet, abnormal cell growth, and more.
To foster safe usage of the over-the-counter (OTC) anti-diarrhea drug loperamide, the U.S. Food and Drug Administration (FDA) is collaborating with manufacturers to use blister packs or other single-dose packaging and to limit the number of doses in a package. Loperamide is an FDA-approved medication used to control diarrhea symptoms, including Travelers’ diarrhea.
The US market dominated the North America Gastrointestinal Therapeutics Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $11, 546.6 million by 2028. The Canada market is poised to grow at a CAGR of 4.9% during (2022-2028). Additionally, The Mexico market should witness a CAGR of 4% during (2022-2028).
Based on Type, the market is segmented into Branded and Generics. Based on Distribution Channel, the market is segmented into Retail Pharmacies, Hospital Pharmacies and Online Pharmacies. Based on Route of Administration, the market is segmented into Injectable and Oral & Others. Based on Application, the market is segmented into Crohn's Disease, Ulcerative Colitis, GERD, IBS and Others. Based on Drug Class, the market is segmented into Biologics/Biosimilar, Anti-Diarrheal, Anti-Emetics, Digestive Enzymes, Aminosalicylates, Proton Pump Inhibitors, Laxatives & H2 Antagonists and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, AbbVie, Inc., Takeda Pharmaceutical Company Limited, Pfizer, Inc., Salix Pharmaceuticals, Inc. (Bausch Health Companies, Inc.), Johnson & Johnson (Janssen Global Services, LLC), AstraZeneca PLC, Bayer AG, Sun Pharmaceutical Industries Ltd., and Cipla Limited.
In many ways, the intestinal milieu represents a microcosm of the whole body. It possesses its intrinsic endocrine and nervous system, its barrier both to internal and external environments of the body, and its own intrinsic mucosal immune system, namely the so-called gut-associated lymphoid tissue (GALT).
Each of these enteric systems can account for pathophysiology and contribute to digestive disorders' clinical picture. Thus, therapeutic intervention for the disease of the GI tract is particularly demanding and should be strategically targeted, with the potential for drug side effects representing considerable accountability.
Gastrointestinal (GI) disease may affect one or more gastrointestinal tract regions, including the esophagus, small & large intestine, stomach, or accessory organs such as the pancreas, gallbladder, and liver. This disease class includes both structural and functional disorders. In addition, GI disorders may arise from diverse etiologies, including pathogens exposure, certain medications, stress, diet, abnormal cell growth, and more.
To foster safe usage of the over-the-counter (OTC) anti-diarrhea drug loperamide, the U.S. Food and Drug Administration (FDA) is collaborating with manufacturers to use blister packs or other single-dose packaging and to limit the number of doses in a package. Loperamide is an FDA-approved medication used to control diarrhea symptoms, including Travelers’ diarrhea.
The US market dominated the North America Gastrointestinal Therapeutics Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $11, 546.6 million by 2028. The Canada market is poised to grow at a CAGR of 4.9% during (2022-2028). Additionally, The Mexico market should witness a CAGR of 4% during (2022-2028).
Based on Type, the market is segmented into Branded and Generics. Based on Distribution Channel, the market is segmented into Retail Pharmacies, Hospital Pharmacies and Online Pharmacies. Based on Route of Administration, the market is segmented into Injectable and Oral & Others. Based on Application, the market is segmented into Crohn's Disease, Ulcerative Colitis, GERD, IBS and Others. Based on Drug Class, the market is segmented into Biologics/Biosimilar, Anti-Diarrheal, Anti-Emetics, Digestive Enzymes, Aminosalicylates, Proton Pump Inhibitors, Laxatives & H2 Antagonists and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, AbbVie, Inc., Takeda Pharmaceutical Company Limited, Pfizer, Inc., Salix Pharmaceuticals, Inc. (Bausch Health Companies, Inc.), Johnson & Johnson (Janssen Global Services, LLC), AstraZeneca PLC, Bayer AG, Sun Pharmaceutical Industries Ltd., and Cipla Limited.
Scope of the Study
By Type
- Branded
- Generics
By Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
By Route of Administration
- Injectable
- Oral & Others
By Application
- Crohn's Disease
- Ulcerative Colitis
- GERD
- IBS
- Others
By Drug Class
- Biologics/Biosimilar
- Anti-Diarrheal
- Anti-Emetics
- Digestive Enzymes
- Aminosalicylates
- Proton Pump Inhibitors
- Laxatives & H2 Antagonists
- Others
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Abbott Laboratories
- AbbVie, Inc.
- Takeda Pharmaceutical Company Limited
- Pfizer, Inc.
- Salix Pharmaceuticals, Inc. (Bausch Health Companies, Inc.)
- Johnson & Johnson (Janssen Global Services, LLC)
- AstraZeneca PLC
- Bayer AG
- Sun Pharmaceutical Industries Ltd.
- Cipla Limited
Unique Offerings
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Gastrointestinal Therapeutics Market, by Type
1.4.2 North America Gastrointestinal Therapeutics Market, by Distribution Channel
1.4.3 North America Gastrointestinal Therapeutics Market, by Route of Administration
1.4.4 North America Gastrointestinal Therapeutics Market, by Application
1.4.5 North America Gastrointestinal Therapeutics Market, by Drug Class
1.4.6 North America Gastrointestinal Therapeutics Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Strategies Deployed in Gastrointestinal Therapeutics Market
Chapter 4. North America Gastrointestinal Therapeutics Market by Type
4.1 North America Branded Market by Country
4.2 North America Generics Market by Country
Chapter 5. North America Gastrointestinal Therapeutics Market by Distribution Channel
5.1 North America Retail Pharmacies Market by Country
5.2 North America Hospital Pharmacies Market by Country
5.3 North America Online Pharmacies Market by Country
Chapter 6. North America Gastrointestinal Therapeutics Market by Route of Administration
6.1 North America Injectable Market by Country
6.2 North America Oral & Others Market by Country
Chapter 7. North America Gastrointestinal Therapeutics Market by Application
7.1 North America Crohn's Disease Market by Country
7.2 North America Ulcerative Colitis Market by Country
7.3 North America GERD Market by Country
7.4 North America IBS Market by Country
7.5 North America Others Market by Country
Chapter 8. North America Gastrointestinal Therapeutics Market by Drug Class
8.1 North America Biologics/Biosimilar Market by Country
8.2 North America Anti-Diarrheal Market by Country
8.3 North America Anti-Emetics Market by Country
8.4 North America Digestive Enzymes Market by Country
8.5 North America Aminosalicylates Market by Country
8.6 North America Proton Pump Inhibitors Market by Country
8.7 North America Laxatives & H2 Antagonists Market by Country
8.8 North America Others Market by Country
Chapter 9. North America Gastrointestinal Therapeutics Market by Country
9.1 US Gastrointestinal Therapeutics Market
9.1.1 US Gastrointestinal Therapeutics Market by Type
9.1.2 US Gastrointestinal Therapeutics Market by Distribution Channel
9.1.3 US Gastrointestinal Therapeutics Market by Route of Administration
9.1.4 US Gastrointestinal Therapeutics Market by Application
9.1.5 US Gastrointestinal Therapeutics Market by Drug Class
9.2 Canada Gastrointestinal Therapeutics Market
9.2.1 Canada Gastrointestinal Therapeutics Market by Type
9.2.2 Canada Gastrointestinal Therapeutics Market by Distribution Channel
9.2.3 Canada Gastrointestinal Therapeutics Market by Route of Administration
9.2.4 Canada Gastrointestinal Therapeutics Market by Application
9.2.5 Canada Gastrointestinal Therapeutics Market by Drug Class
9.3 Mexico Gastrointestinal Therapeutics Market
9.3.1 Mexico Gastrointestinal Therapeutics Market by Type
9.3.2 Mexico Gastrointestinal Therapeutics Market by Distribution Channel
9.3.3 Mexico Gastrointestinal Therapeutics Market by Route of Administration
9.3.4 Mexico Gastrointestinal Therapeutics Market by Application
9.3.5 Mexico Gastrointestinal Therapeutics Market by Drug Class
9.4 Rest of North America Gastrointestinal Therapeutics Market
9.4.1 Rest of North America Gastrointestinal Therapeutics Market by Type
9.4.2 Rest of North America Gastrointestinal Therapeutics Market by Distribution Channel
9.4.3 Rest of North America Gastrointestinal Therapeutics Market by Route of Administration
9.4.4 Rest of North America Gastrointestinal Therapeutics Market by Application
9.4.5 Rest of North America Gastrointestinal Therapeutics Market by Drug Class
Chapter 10. Company Profiles
10.1 Abbott Laboratories
10.1.1 Company Overview
10.1.2 Financial Analysis
10.1.3 Segmental and Regional Analysis
10.1.4 Research & Development Expense
10.1.5 SWOT Analysis
10.2 AbbVie, Inc.
10.2.1 Company Overview
10.2.2 Financial Analysis
10.2.3 Regional Analysis
10.2.4 Research & Development Expense
10.2.5 Recent strategies and developments:
10.2.5.1 Approvals and Trials:
10.3 Takeda Pharmaceutical Company Limited
10.3.1 Company Overview
10.3.2 Financial Analysis
10.3.3 Regional Analysis
10.3.4 Research & Development Expense
10.3.5 Recent strategies and developments:
10.3.5.1 Partnerships, Collaborations, and Agreements:
10.3.5.2 Acquisition and Mergers:
10.4 Pfizer, Inc.
10.4.1 Company Overview
10.4.2 Financial Analysis
10.4.3 Regional & Segmental Analysis
10.4.4 Research & Development Expense
10.4.5 Recent strategies and developments:
10.4.5.1 Partnerships, Collaborations, and Agreements:
10.5 Salix Pharmaceuticals, Inc. (Bausch Health Companies, Inc.)
10.5.1 Company Overview
10.5.2 Financial Analysis
10.5.3 Segmental and Regional Analysis
10.5.4 Research & Development Expense
10.5.5 Recent strategies and developments:
10.5.5.1 Product Launches and Product Expansions:
10.6 Johnson & Johnson (Janssen Global Services, LLC)
10.6.1 Company Overview
10.6.2 Financial Analysis
10.6.3 Segmental &Regional Analysis
10.6.4 Research & Development Expenses
10.6.5 Recent strategies and developments:
10.6.5.1 Partnerships, Collaborations, and Agreements:
10.7 AstraZeneca PLC
10.7.1 Company Overview
10.7.2 Financial Analysis
10.7.3 Regional Analysis
10.7.4 Research & Development Expenses
10.8 Bayer AG
10.8.1 Company Overview
10.8.2 Financial Analysis
10.8.3 Segmental and Regional Analysis
10.8.4 Research & Development Expense
10.9 Sun Pharmaceutical Industries Ltd.
10.9.1 Company Overview
10.9.2 Financial Analysis
10.9.3 Research & Development Expenses
10.10. Cipla Limited
10.10.1 Company Overview
10.10.2 Financial Analysis
10.10.3 Regional Analysis
10.10.4 Research & Development Expense
Companies Mentioned
- Abbott Laboratories
- AbbVie, Inc.
- Takeda Pharmaceutical Company Limited
- Pfizer, Inc.
- Salix Pharmaceuticals, Inc. (Bausch Health Companies, Inc.)
- Johnson & Johnson (Janssen Global Services, LLC)
- AstraZeneca PLC
- Bayer AG
- Sun Pharmaceutical Industries Ltd.
- Cipla Limited
Methodology
LOADING...
